PD-1 Inhibitors in Recurrent or Metastatic Oral Squamous Cell Carcinoma: Clinical Evidence, Patient Selection, and Immune-Related Toxicities. J Oral Health Dent Ther [Internet]. 2026 Oct. 30 [cited 2026 Nov. 6];1(1):27-31. Available from: https://msarjournals.com/index.php/johdt/article/view/13